Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations.

Medicine - 12 Sept 2025

Zhang Shiyu, Liu Jingwen, Liu Jia, Lu Kaihua

Abstract excerpt

Targeted therapy has greatly improved the survival time and quality of life of some patients with non-small cell lung cancer. The application of immunotherapy among populations without targetable oncogenes has also achieved great success. However, the decision is still inconclusive as to whether immunotherapy can be used in targeted populations. We screened studies related to immunotherapy for lung cancer from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Immunotherapy

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 40958347
DOI: 10.1097/MD.0000000000044144
PMCID: PMC12440478

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations.PMID 40958347Read ↗

Immunotherapy in non-small cell lung cancer harbouring driver mutations.Semantic proximity Read ↗

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.Semantic proximity Read ↗

Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Targeted Therapy and Immunotherapy for Lung Cancer.Semantic proximity Read ↗

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read ↗

Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

[The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].Semantic proximity Read ↗

Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisSemantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.